Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology

Nutriband Inc. (NASDAQ: NTRB) has achieved a milestone in the pharmaceutical industry by securing U.S. patent No. 12,318,492 for its 'Abuse and Misuse Deterrent Transdermal Systems.' This patent, awarded on June 3, 2025, fortifies the company's intellectual property rights over its Aversa(TM) technology, designed to combat the misuse, diversion, and accidental exposure of drugs with abuse potential. The technology is a cornerstone of Nutriband's lead product, Aversa Fentanyl, which is poised to become the first abuse-deterrent fentanyl patch available in the market, with projected peak U.S. sales ranging between $80 million and $200 million.

The significance of this development cannot be overstated, as it represents a critical advancement in addressing the opioid crisis. By integrating Aversa(TM) technology into transdermal patches, Nutriband is setting a new standard for safety in the administration of potent medications. This innovation not only has the potential to save lives by reducing the risk of abuse but also positions Nutriband as a leader in the development of abuse-deterrent pharmaceutical products. The granting of this patent underscores the importance of continued investment in technologies that can mitigate the public health challenges posed by drug abuse.